Torrent and Zydus Join Forces to Combat Liver Disorders

14
Business deal Joins hand Collaboration
Picture: Pixabay

Last Updated on December 31, 2023 by The Health Master

Torrent and Zydus

Torrent and Zydus: In a significant move towards advancing healthcare, Torrent Pharmaceuticals announced a groundbreaking licensing agreement with Zydus Lifesciences.

This collaboration aims to co-market a revolutionary product for the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) in India.

Let’s delve into the details of this strategic partnership.

Saroglitazar Mg: A Beacon of Hope for Liver Disorders

At the heart of this collaboration lies Saroglitazar Magnesium, the only approved drug for NASH and NAFLD in India.

With the prevalence of these progressive liver disorders on the rise, the significance of Saroglitazar Mg cannot be overstated.

This drug is poised to play a pivotal role in managing and mitigating the impact of NASH and NAFLD.

Navigating the Licensing Agreement Landscape

Under the licensing agreement, Torrent Pharmaceuticals secures semi-exclusive rights to co-market Saroglitazar Mg in India, branding it as Vorxar.

Zydus Lifesciences, the innovator of the drug, retains the rights to market it under the brand names Lipaglyn and Bilypsa.

The agreement also outlines financial commitments, with Torrent providing upfront licensing fees and milestone payments tied to specific achievements.

Financial Commitments and Strategic Branding

Torrent’s financial commitment underscores the company’s dedication to advancing healthcare solutions.

The semi-exclusive rights to co-market Vorxar present a unique opportunity for Torrent to strengthen its gastroenterology franchise.

Zydus Lifesciences’ Ongoing Role

Zydus Lifesciences, having introduced Saroglitazar Mg under different brand names, remains committed to its marketing strategies.

The association with Torrent signifies a shared vision of expanding the drug’s reach and impact.

Saroglitazar Mg: Bridging Global Treatment Gaps

While Saroglitazar Mg stands as the only approved drug for NASH and NAFLD in India, it’s important to note the absence of approved drugs for these disorders globally.

This collaboration marks a step towards addressing this treatment gap on a larger scale.

Impact on Torrent’s Gastroenterology Franchise

Aman Mehta, Director of Torrent Pharmaceuticals, expressed optimism about the agreement’s potential to enhance the company’s gastroenterology franchise.

This collaboration aligns with Torrent’s commitment to providing innovative solutions for critical medical needs.

Aligning for Long-term Vision

Sharvil Patel, Managing Director of Zydus Lifesciences, highlighted the association with Torrent as a testament to their long-term vision.

The collaboration reflects a shared commitment to advancing healthcare solutions and making a meaningful impact on patient lives.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news